Yoshiki Horie

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada et al. · Journal of Clinical Oncology · 2020 · 197 citations

Medicine, Oncology, Pharmacotherapy +16

Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis

Kyoichi Kaira, Yoshiki Horie, Eriko Ayabe et al. · Journal of Thoracic Oncology · 2010 · 131 citations

Medicine, Oncology, Pathology +12

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Toshio Shimizu, Takako Eguchi Nakajima, Noboru Yamamoto et al. · Investigational New Drugs · 2022 · 48 citations

Life Sciences, Immunology, Oncology +14

A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).

Akitaka Makiyama, Kosuke Sagara, Junji Kawada et al. · Journal of Clinical Oncology · 2018 · 36 citations

Medicine, Oncology, Pharmacology +9

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Takeshi Suzuki, Yasutaka Sukawa, Chiyo K. Imamura et al. · Clinical Colorectal Cancer · 2019 · 30 citations

Medicine, Pharmacokinetics, Pharmacology +14